Related Experiment Video
Updated: May 31, 2026
Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
Published on: June 9, 2023
[Antitumor effects of sulindac in ovarian cell cultures]
Anna Jakubowska-Mućka1, Jacek Sieńko, Tomasz Switaj
1Zakład Immunologii, Centrum Onkologii - Instytut im. Marii Sklodowskiej-Curie, Warszawa, Polska.
Objective:
The purpose of our study was to assess susceptibility of cells of various ovarian cell lines on different nonsteroidal anti-inflammatory drugs (NSAIDs).
Materials And Methods:
Cytotoxic effect of NSAIDs was tested using MTT colorimetric assay.
Results:
Amongst 6 NSAIDs tested: sulindac, sulindac sulfide, sulindac sulfone, acetylsalicylic acid, nimesulide, and rofecoxib, viability of ovarian carcinoma cells was compromised most strongly by sulindac and sulindac sulfide and concerned all the cell lines tested: SKOV-3, MDAH 2774, OVCA-1, and OVP-10. Sulindac sulfone and rofecoxib also displayed some cytotoxic effect during prolonged 72-hour incubation. Other NSAIDs tested: nimesulide and acetylsalicylic acid were devoid of cytotoxic effect on ovarian cancer cells.
Conclusion:
Our results are encourage enough to conduct clinical trials that could allow to draw conclusions regarding potential application of sulindac in the adjuvant treatment of a standard chemotherapy of ovarian cancer.
Insights
Sulindac and sulindac sulfide show significant cytotoxic effects on ovarian cancer cells, suggesting potential for adjuvant therapy. Further clinical trials are warranted to explore sulindac
Area of Science:
- Oncology
- Pharmacology
Context:
- Ovarian cancer remains a significant health challenge.
- Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for pain and inflammation.
- Investigating novel therapeutic strategies for ovarian cancer is crucial.
Purpose:
- To evaluate the in vitro susceptibility of various ovarian cancer cell lines to different nonsteroidal anti-inflammatory drugs (NSAIDs).
- To identify specific NSAIDs with potent cytotoxic effects against ovarian carcinoma cells.
Summary:
- Six NSAIDs were tested: sulindac, sulindac sulfide, sulindac sulfone, acetylsalicylic acid, nimesulide, and rofecoxib.
- Sulindac and sulindac sulfide demonstrated the strongest cytotoxic effects across all tested ovarian cancer cell lines (SKOV-3, MDAH 2774, OVCA-1, OVP-10).
- Sulindac sulfone and rofecoxib exhibited some cytotoxicity with prolonged incubation (72 hours), while nimesulide and acetylsalicylic acid showed no significant effect.
Impact:
- The findings support the potential of sulindac as an adjuvant therapy in standard ovarian cancer chemotherapy.
- Encourages clinical trials to validate the efficacy of sulindac in ovarian cancer treatment.
- Highlights the differential cytotoxic effects of various NSAIDs on ovarian cancer cells, guiding future drug development.
